MaaT Pharma Overview
- Founded
-
2014

- Status
-
Public
- Employees
-
33

- Stock Symbol
-
MAAT

- Share Price
-
$10.53
- (As of Friday Closing)
MaaT Pharma General Information
Description
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Primary Office
- 70 Avenue Tony Garnier
- 69007 Lyon
- France
+33 04 00 00 00 00
MaaT Pharma Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$10.53 | $10.61 | $10.03 - $16.66 | $105M | 9.9M | 510.79 | -$4.37 |
MaaT Pharma Financials Summary
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 137,385 | 137,385 | ||
Revenue | 1,149 | 1,149 | 0 | 0 |
EBITDA | (10,132) | (10,132) | (5,804) | (6,411) |
Net Income | (10,663) | (10,663) | (6,043) | (6,542) |
Total Assets | 55,954 | 55,954 | 29,859 | 9,152 |
Total Debt | 6,574 | 6,574 | 7,473 | 11,723 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
MaaT Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
MaaT Pharma Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
MaaT Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapi
Drug Discovery
Lyon, France
33
As of 2021
000.00
0000
0000-00-00
00000000
000.00
MaaT Pharma Competitors (16)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Axial Therapeutics | Venture Capital-Backed | Woburn, MA | 00 | 00000 | 00000000000 | 00000 |
00000 00000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
00000 | Formerly VC-backed | Somerville, MA | 000 | 00000 | 00000000 | 00000 |
00000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
00000000 | Venture Capital-Backed | Paris, France | 00 | 00000 | 0000000000 0 | 00000 |
MaaT Pharma Patents
MaaT Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3895716-A4 | Fmt performance prediction test to guide and optimize therapeutic management of gvhd patients | Ceased | 17-Apr-2020 | 000000000 | |
EP-3895716-A1 | Fmt performance prediction test to guide and optimize therapeutic management of gvhd patients | Ceased | 17-Apr-2020 | 000000000 | 0 |
EP-3597202-A1 | Fecal microbiota composition, for use in reducing treatment-induced inflammation | Ceased | 20-Jul-2018 | 000000000 | 0 |
US-20210299188-A1 | Fecal microbiota composition for use in reducing treatment-induced inflammation | Pending | 20-Jul-2018 | 000000000 | |
JP-2021530527-A | Fecal microflora composition for use in reducing treatment-induced inflammation | Granted | 20-Jul-2018 | A61K35/38 |
MaaT Pharma Executive Team (12)
MaaT Pharma Board Members (15)
Name | Representing | Role | Since |
---|---|---|---|
Claude Bertrand | MaaT Pharma | Board Member | 000 0000 |
Dorothée Burkel | Self | Board Member | 000 0000 |
Herve Affagard | MaaT Pharma | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
Isabelle de Cremoux | Seventure Partners | Board Member | 000 0000 |
Jean Volatier | Self | Board Member | 000 0000 |